GLP-1 Receptor Agonist Market Share Companies such as Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi dominate this market due to their strong research capabilities, innovative drug formulations, and commitment to addressing diabetes and obesity challenges
Shima Hadidchi, MD Board-certified and experienced primary care physician, Dr
Despite likely being a similar tier as GLP-1 RAs and SGLT2is for many patient insurances, this elevated AWP is important to note for patients with co-insurances, deductibles, the Medicare coverage gap, patients without insurance, and for the total cost of healthcare
Contrary to common belief, caffeinated beverages do generally count toward hydration goals, though moderation is advised (FDA considers up to 400mg caffeine daily generally safe for most adults)
Obesity increases the risk of small intestinal bacterial overgrowth (SIBO)
In native GLP-1, this position holds an alanine residue, and it is exactly where DPP-4 attacks